A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

About this Study

The purpose of this research study is to learn about the effects of the study drug and to find the best dose for treating small cell lung cancer, castration resistant prostate cancer, and follicular lymphoma, as well as to learn about the safety of the study drug and how it is absorbed, distributed, broken down, and removed from the body.

Sponsor Protocol ID:C2321001
IRB Number:2020-0028
Actively Enrolling
Interventional
Phase 1
February 20, 2020
Eligibility Criteria
18 years old
Both Male and Female
Yes
No
No

Inclusion CriteriaFemales and/or male patients age 18 years and older.

Exclusion CriteriaHistory of alcohol abuse or binge drinking [more than 4 drinks on any day or 14 drinks per week where 1 drink is defined as the alcoholic beverage containing approximately (1 unit = 8 ounces (240 mL) beer, 1 ounce (30 mL) of 40% spirit or 3 ounces (90 mL) of wine)] in the last 6 months prior to study screening. 

Radiation therapy within 4 weeks prior to study entry. 

Categories Click category to view its trials.
Cancer
Lungs/Breathing
Participating Locations
Cancer Center and Research Institute
University Hospital
Contact Information
Contact Name: Jennifer Barnes
Phone Number: 601-815-4540
Email: jbarnes@umc.edu
Principal Investigator:Tang, Shou-Ching, M.D.
How to participate in our Clinical Trials